Reduced frequency of severe hypoglycemia and coma well-controlled IDDM patients treated with insulin lispro

Diabetes Care

Volumn 20, Issue 12, 1997, Pages 1827-1832

  Holleman, Frits ^a   Schmitt, Henry ^b   Rottiers, Raoul ^c   Rees, Alan ^d   Symanowski, Sharon ^b   Anderson, James H ^b  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULINEMIA; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030782101     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.12.1827     Document Type: Article

References (36)

1. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U: Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 230:101-108, 1991
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Zinman B: Insulin regimens and strategies for IDDM: Diabetes Care 16 (Suppl. 3):24-28, 1993
4. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics. Diabetes Care 7:188-199, 1984
5. Heinemann L, Richter B: Clinical pharmacology of human insulin. Diabetes Care 16 (Suppl. 3):90-100, 1993
6. Dimitriadis GD, Gerich JE: Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6:374-377, 1983
7. Lean MEJ, Ng LL, Tennison BR: Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J 290:105-108, 1985
8. The DCCT Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450-459, 1991
9. The Diabetes Control and Complications Trial Research Group: Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 18:1415-1427, 1995
10. Macleod KM, Hepburn DA, Frier BM: Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238-245, 1993
11. Wredling RAM, Töres Theorell PG, Roll HM, Lins PES, Adamson UKC: Psychosocial state of patients with IDDM prone to recurrent episodes of severe hypoglycemia. Diabetes Care 15:518-521, 1992
12. Pramming S, Thorsteinsson B, Bendtson I, Binder C: The relationship between symptomatic and biochemical hypoglycaemia in insulin-dependent diabetic patients. J Intern Med 228:641-646, 1990
13. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sorensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682, 1988
14. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9,GluB27; AspB10; AspB28) on meal related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14:571-577, 1991
15. Heinemann L, Heise T, Jørgensen LN, Starke AAR: Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10:535-539, 1993
16. Nielsen FS, Jørgensen LN, Ipsen M, Voldsgaard AI, Parving HH: Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592-598, 1995
17. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28),Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
18. Vignati L, Anderson J, Brunelle R: Efficacy of [Lys(B28),Pro(B29)] human insulin in a 1-year global randomized clinical trial (Abstract). Diabetes 42 (Suppl. 1):78A, 1994
19. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R, the Multicenter Insulin Lispro Study Group: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265-270, 1997
20. Anderson J, Symanowski S, Brunelle R: Safety of [Lys(B28),Pro(B29)] human insulin analog in long-term clinical trials (Abstract). Diabetes 43 (Suppl. 1):61A, 1994
21. Pfützner A, Küstner E, Forst T, Schulze-Schleppinghof B, Trautmann ME, Haslbeck M, Schatz H, Beyer J: Intensive insulin therapy with insulin lispro in patients with type I diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol 104:25-30, 1996
22. Anderson JH, Brunelle RL, Arora V, Phillips JS, Vignati L, Koivisto VA, Trautmann ME: Effect of basal insulin on reduced frequency of nocturnal hypoglycemia in patients treated with insulin lispro (Abstract). Diabetologia 39 (Suppl. 1):A221, 1996
23. Pickup JC: Brittle diabetes. In International Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. John Wiley, New York, 1992, p. 1060
24. Pramming S, Thorsteinsson B, Bendtson I, Rønn B, Binder C: Nocturnal hypoglycaemia in patients receiving conventional treatment with insulin. Br Med J 291:376-379, 1985
25. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diatoologia 37:713-720, 1994
26. Jacobs MAJM, Salobir B, Aarsen M, van Iperen A, Heine RJ: Hypoglycaemic thresholds for the glucose counterregulatory responses to Lys(B28)Pro(B29) human insulin analog. Horm Metab Res 26:A34, 1994
27. Tsui E, Chiasson JL, Tildesley H, Barnie A, Simkins S, Gao XJ, Zinman B: The use of insulin lispro in subcutaneous insulin pumps: counterregulatory hormone responses (Abstract). Diabetologia 39 (Suppl. 1):A223, 1996
28. Pramming S, Thorsteinsson B, Bendtson I, Binder C: Symptomatic hypoglycaemia in 411 type I diabetic patients. Diabet Med 8:217-222, 1991
29. Jørgensen LN, Nielsen FS: Timing of premeal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study (Abstract). Diabetologia 33 (Suppl. 1):A116, 1990
30. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII. Diabetes 46:440-443, 1997
31. Delahanty LM, Halford B: The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care 16:1453-1458, 1993
32. Karsidag K, Satman I, Dinççag N, Altuntas Y, Karadeniz Ş, Yilmaz MT: Comparison of metabolic control in IDDM with two different intensive regimens of [Lys(B28), Pro(B29)]-human insulin (lispro) plus NPH insulin (Abstract). Diabetologia 39 (Suppl. 1):A222, 1996
33. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
34. Talaulicar M, Willms B, Roßkamp R: Efficacy of HOE901 following subcutaneous injection for four days in type I diabetic subjects (Abstract). Diabetologia 37 (Suppl. 1):A169, 1994
35. Myers S, Yakubu-Madus F, Johnson W, Baker J, Cusick T, Williams V, Tinsley F, Kriauciunas A, Chen V: W99-S32: a soluble, basal insulin analog (Abstract). Diabetologia 38 (Suppl. 1):A4, 1995
36. Jonassen I, Havelund S, Kurtzhals P, Halstrom J, Ribel U, Hasselager E, Larsen UD, Markussen J: The potential therapeutic advantage of a novel, protracted, neutral soluble, albumin binding insulin analogue (Abstract). Diabetologia 38 (Suppl. 1):A4, 1995